HC Wainwright & Co. reiterated coverage on Salarius Pharmaceuticals with a new price target

HOUSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) announces that patient enrollment will resume in the investigator-initiated Phase 1/2 clinical trial evaluating seclidemstat in combination with azacitidine for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted at the University of Texas MD Anderson Cancer Center (MDACC) and is listed as recruiting on clinical trials.gov – trial NCT04734990. Seclidemstat is a novel oral reversible inhibitor of the LSD1 enzyme. Inhibiting LSD1 in preclinical in vivo hematologic models has previously demonstrated reprogramed cancer cell differentiat

Decoy's proprietary IMP3ACT™ peptide conjugate drug design and manufacturing platform leverages machine learning (ML) and artificial intelligence (AI) tools Decoy is leveraging non-dilutive funding and equivalents from federal governments, corporations and The Bill & Melinda Gates Foundation totaling approximately $7 million Combined company expects to accelerate clinical development of novel peptide conjugate therapeutics for the treatment of respiratory viruses and cancer HOUSTON and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing therapies for patients with cancer in need of new tr

Patients were treated in the dose-escalation portion of the Phase 1/2 study evaluating seclidemstat in combination with azacitidine Investigators reported a 43% overall response rate among 14 predominantly higher risk myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) patients who previously failed or relapsed after hypomethylating agent therapy Median overall survival was 18.5 months (95% CI, range 6.1-30.9 months) with median event-free survival of 7.2 months (95% CI, range 6.3-8.2 months) HOUSTON, June 17, 2024 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degrad

HC Wainwright & Co. reiterated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $4.00 from $5.00 previously

HC Wainwright & Co. initiated coverage of Salarius Pharmaceuticals with a rating of Buy and set a new price target of $5.00

4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

4 - Salarius Pharmaceuticals, Inc. (0001615219) (Issuer)

8-K - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

424B5 - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

S-1 - Salarius Pharmaceuticals, Inc. (0001615219) (Filer)

HOUSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing potential new medicines for patients with sarcomas, pediatric cancers, and other cancers, today announced that Daniela Santiesteban, Ph.D., has been named Director of the Company's new targeted protein degradation program. In this newly created position, Dr. Santiesteban will assume responsibility for overseeing the development of SP-3164, the program's lead drug candidate, and advancing it into clinical trials. Her appointment immediately follows Salarius' recent strategic expansion into the targeted protein degradation field through its acquisitio

HOUSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, will hold a conference call with slides to discuss recent clinical and preclinical data from its lead programs on December 14, 2022 at 11:00 a.m. Eastern time. Management will review recently announced interim results from its ongoing Phase 1/2 trial with seclidemstat in Ewing sarcoma and FET-rearranged sarcomas, as well as new clinical data from MD Anderson Cancer Center's study with seclidemstat plus azacytidine in hematological cancer

60% Confirmed Disease Control Rate1 and 7.4 Months Median Time to Tumor Progression for Ewing Sarcoma First-Relapse Patients No Disease Progression Observed in Either First- or Second-Relapse Ewing Sarcoma Patients Who Achieved Confirmed Disease Control HOUSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company using targeted protein inhibition and targeted protein degradation to develop therapies for patients with cancer in need of new treatment options, announces interim clinical trial results from the company's Phase 1/2 trial of its novel oral, reversible, targeted LSD1 inhibitor, seclidemstat, as a treatment fo

HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX), a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options, today reported financial results for the three and six months ended June 30, 2022, and provided a business update. Highlights of the quarter and recent weeks included: Financial Highlights Cash and equivalents were $22.6 million as of June 30, 2022, compared with $29.2 million as of December 31, 2021Tightly managed expenses while progressing toward multiple near-term milestonesNet loss of $4.7 million, or $0.09 per share, compared with net loss of $3.1 million, or $0.07 per share,

SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

SC 13G - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)

SC 13G/A - Salarius Pharmaceuticals, Inc. (0001615219) (Subject)